Additional file 1 of Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

Additional file 1: Supplementary Table 1. Drop-outs and adverse event reporting. Supplementary Table 2. Monthly headache days, monthly migraine days and days of acute drug intake according to MIDAS and monthly migraine days (MMDs) response at T3. Supplementary Table 3. Patients’ reported outcomes according to MIDAS and monthly migraine days (MMDs) response at T3.